跳至主要内容
临床试验/NCT07688447
NCT07688447招募中不适用

Multicenter Randomized Controlled Trial of ThuLEP Versus ThuLEP Combined With Bladder Neck Incision in Patients With Small-Volume Benign Prostatic Hyperplasia

Shanghai General Hospital, China1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2026年7月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
120
试验地点
1
主要终点
Maximum flow rate (Qmax)

研究概览

简要总结

With the increasing degree of population aging, the number of patients undergoing surgical treatment for benign prostatic hyperplasia (BPH) is steadily rising. Among them, patients with small-volume prostates (≤30 mL) represent a distinct clinical subgroup.

This population has several unique characteristics:

  1. Approximately 17.5% of patients show suboptimal postoperative outcomes.
  2. The incidence of postoperative bladder neck contracture (BNC) is relatively high, reaching up to 19.3% in some reports.

In addition, the pathophysiological mechanisms of small-volume BPH are different from those of larger prostates. These include increased fibrotic tension of the bladder neck and bladder neck elevation.

At present, there is no clearly established surgical approach specifically designed to further improve postoperative outcomes or effectively prevent bladder neck contracture in patients with small-volume BPH.

This study primarily compares the safety and efficacy of transurethral thulium laser enucleation of the prostate (ThuLEP) versus ThuLEP combined with bladder neck incision in the treatment of small-volume benign prostatic hyperplasia (BPH), with the aim of further optimizing surgical management strategies for small prostates and reducing the incidence of postoperative complications.

详细描述

Benign prostatic hyperplasia (BPH) is a common urological disease in middle-aged and elderly men. With the acceleration of population aging in China, the incidence of BPH is continuously increasing. Domestic epidemiological data show that the prevalence of histological BPH is approximately 20% in men aged 50-60 years, 50% in those aged 61-70 years, 57.1% in those aged 71-80 years, and 83.3% in those aged 81-90 years. BPH leads to bladder outlet obstruction and changes in lower urinary tract symptoms, thereby significantly affecting patients' quality of life, and in advanced stages may result in bladder and renal dysfunction.

Transurethral resection of the prostate (TURP) has long been regarded as the "gold standard" for the surgical management of BPH by urologists. However, its application is limited by relatively high rates of postoperative complications, including bleeding, bladder neck contracture, urethral stricture, TUR syndrome, and a considerable reoperation rate. With the development and increasing application of laser technologies in urology, laser-based procedures have demonstrated growing advantages in the treatment of BPH.

Thulium (Tm) laser is a novel medical laser technology with a wavelength range of 1.75-2.22 μm. Thulium laser technology is characterized by simplicity of operation, minimal tissue injury, excellent hemostatic capability, and high precision. In recent years, it has developed rapidly and been widely adopted in urology. Transurethral thulium laser enucleation of the prostate is considered safe and efficient, with an easy learning curve, relatively short training period, and lower procedural cost, thus demonstrating broad clinical prospects.

The pathophysiology of bladder outlet obstruction in BPH can be divided into two major components: dynamic factors (increased smooth muscle tone of the prostate) and mechanical factors (urethral compression due to prostate enlargement) . Unlike large prostates (>80 mL), in most small-volume BPH cases, mechanical compression of the posterior urethra is not the predominant cause of obstruction. Some studies suggest that the main pathophysiological mechanisms in small prostates include bladder neck fibrosis, increased fibrous ring tension, and chronic prostatitis . In addition, bladder neck elevation and an increased prostatic urethral angle are also closely associated with lower urinary tract obstruction symptoms in this population.

Based on these considerations, we propose a combined surgical approach consisting of transurethral laser enucleation of the prostate combined with bladder neck longitudinal incision. By surgically incising the bladder neck, this technique may simultaneously address both prostatic hyperplasia and bladder neck abnormalities. For patients with small prostates accompanied by bladder neck stenosis, fibrosis, or anatomical abnormalities (such as bladder neck elevation), this combined procedure may effectively correct both tissue obstruction and bladder neck dysfunction in a single stage.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
50 Years 至 85 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Male patients aged 50-85 years who meet the diagnostic criteria for benign prostatic hyperplasia (BPH), with a prostate volume ≤30 mL and requiring surgical intervention.
  • Preoperative International Prostate Symptom Score (IPSS) ≥
  • Preoperative maximum urinary flow rate (Qmax) ≤15 mL/s.
  • Bladder capacity ≥150 mL.
  • Willing to participate in this clinical trial and has signed the informed consent form.
  • Able to communicate well with investigators and comply with the study protocol requirements.

排除标准

  • Patients with urethral stricture in whom passage of surgical instruments is not feasible.
  • Total PSA >10 ng/mL, or PSA between 4-10 ng/mL with a free-to-total PSA ratio <0.16, and confirmed malignancy on biopsy.
  • Coagulation disorders, including platelet count <80 × 10⁹/L.
  • Uncontrolled urinary tract infection.
  • Neurogenic bladder.
  • Presence of malignant tumors.
  • Urodynamic diagnosis of bladder neck sclerosis, detrusor underactivity, detrusor-sphincter dyssynergia, or unstable bladder.
  • Contraindications to surgery, such as severe cardiopulmonary disease.
  • Cognitive impairment, including senile dementia, cerebral atrophy, acute cerebrovascular disease, sequelae of cerebrovascular disease, or other conditions affecting cognitive function.
  • History of suprapubic cystostomy for benign prostatic hyperplasia.
  • Acute localized or systemic bacterial infection that has not been effectively controlled.
  • Presence of shock or other critical conditions that preclude cooperation with the procedure and outcome evaluation.
  • Psychiatric or neurological disorders preventing cooperation with the study.
  • Participation in another clinical trial within 1 month prior to enrollment.
  • Any other condition deemed inappropriate for inclusion by the investigators.

研究组 & 干预措施

Control group

Experimental

Patients in the control group will be treated with ThuLEP

干预措施: Transurethral Thulium Laser Enucleation of the Prostate (ThuLEP) (Procedure)

Intervention group

Experimental

Patients in the intervention group will be treated with ThuLEP combined with transurethral bladder neck Incision

干预措施: ThuLEP combined with transurethral bladder neck incision (Procedure)

结局指标

主要结局

Maximum flow rate (Qmax)

时间窗: The sixth month after the operation

Based on similar clinical studies, the primary efficacy endpoint was defined as the maximum urinary flow rate (Qmax) at 6 months postoperatively. In patients with small-volume prostates, the underlying pathophysiological mechanisms commonly include bladder neck fibrosis, increased fibrotic ring tension, and chronic prostatitis. In addition, bladder neck elevation and an increased prostatic urethral angle are also closely associated with lower urinary tract obstruction symptoms in this subgroup. In the experimental group, a combined surgical approach was applied. By performing a bladder neck incision, this technique may simultaneously address both prostatic tissue hyperplasia and bladder neck abnormalities in patients with small prostates who present with bladder neck stenosis, fibrosis, or anatomical alterations such as bladder neck elevation. Therefore, this combined approach may potentially lead to greater improvement in postoperative urinary flow parameters.

次要结局

  • International prostate symptom score (IPSS)(Perioperative period and 1st, 3rd, and 6th months after the operation)
  • Quality of life score(QoL)(Perioperative period and 1st, 3rd, and 6th months after the operation)
  • Post-void residual urine volume (PVR)(Perioperative period and 1st, 3rd, and 6th months after the operation)
  • maximum flow rate (Qmax)(The 1st and 3rd months after the operation)
  • Incidence of bladder neck contracture(The 1st, 3rd and 6th months after the operation)
  • Complete blood count(Within 3 days before the operation and the first day of the operation)
  • Urinalysis(Within 3 days before the operation and at 3 and 6 months postoperatively.)

研究者

发起方
Shanghai General Hospital, China
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yifeng Jing

Professor

Shanghai General Hospital, China

研究点 (1)

Loading locations...

相似试验